Cannata, F., Chiarito, M., Reimers, B., Azzolini, E., Ferrante, G., My, I., … Stefanini, G. G. (2020). Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother, 6(6), 412–414. https://doi.org/10.1093/ehjcvp/pvaa056

Cannata, Francesco, Mauro Chiarito, Bernhard Reimers, Elena Azzolini, Giuseppe Ferrante, Ilaria My, Giacomo Viggiani, et al. “Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality.” Eur Heart J Cardiovasc Pharmacother 6, no. 6 (November 1, 2020): 412–14. https://doi.org/10.1093/ehjcvp/pvaa056.

Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, et al. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):412–4.

Cannata, Francesco, et al. “Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality.” Eur Heart J Cardiovasc Pharmacother, vol. 6, no. 6, Nov. 2020, pp. 412–14. Pubmed, doi:10.1093/ehjcvp/pvaa056.

Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, Viggiani G, Panico C, Regazzoli D, Ciccarelli M, Voza A, Aghemo A, Li H, Wang Y, Condorelli G, Stefanini GG. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):412–414.